Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on International Tech Times.
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
GlobeNewswire
·
May 31, 2025
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a clinically meaningful increase in median overall survival (10.1 months vs 7.2 months; log-rank p=0.01) in previously untreated patients with metastatic pancreatic ductal …
PlanChecker AI Launches with the Goal to Rewire the Infrastructure of Real Estate Development
EIN Presswire
·
May 31, 2025
LOS ANGELES, CA, UNITED STATES, May 31, 2025 /EINPresswire.com/ -- Co-founded by veteran real estate developer Matthew Raanan and senior software engineer Justine Raanan, the Los Angeles-based startup PlanCheker AI launches as an innovative compliance …
Trade 350 App: This Trade 350 App Sets New Standard in AI-Driven Trading with Unmatched Security and User Approval
GlobeNewswire
·
May 31, 2025
New York City, NY, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction In the crowded world of online trading platforms, separating legitimate services from elaborate scams can be a daunting task. Trade 350 App has emerged as one of the buzziest names in 2025, …
Starscope: Does Starscope Monocular Really Work for Stargazing & Hiking? Read Full Starscope Monocular Telescope Consumer Report!
GlobeNewswire
·
May 31, 2025
San Diego, CA, May 31, 2025 (GLOBE NEWSWIRE) -- Introduction: Why the Starscope Monocular Is Gaining Popularity in 2025 Whether you're a nature lover, hiker, hunter, or stargazer, having the right optical gear can make or break your outdoor experience. In …
Robex gibt Abschluss des Börsengangs bekannt
GlobeNewswire
·
May 31, 2025
STADT QUÉBEC, May 31, 2025 (GLOBE NEWSWIRE) -- Der westafrikanische Goldproduzent und -erschließer Robex Resources Inc („Robex“ oder das „Unternehmen“) (TSX-V: RBX) freut sich bekannt zu geben, dass das Unternehmen den Börsengang an der Australian …
Robex annonce la finalisation de son introduction en bourse
GlobeNewswire
·
May 31, 2025
QUÉBEC, 31 mai 2025 (GLOBE NEWSWIRE) -- Robex Resources Inc. (« Robex » ou la « Société ») (TSX-V : RBX), producteur et développeur aurifère ouest-africain, a le plaisir d’annoncer le succès de son introduction sur la bourse australienne (« ASX ») avec 38 …
JAMining Expands FCA-Regulated Cloud Mining Services Amid Surging Crypto Market Activity
GlobeNewswire
·
May 31, 2025
Image by JAMining LONDON, May 31, 2025 (GLOBE NEWSWIRE) -- JAMining, a UK-based cloud mining provider regulated by the Financial Conduct Authority (FCA), has announced a major expansion of its services. This strategic move comes amid a surge in global …
PAIRMiner Makes Bitcoin Mining More Accessible Amid Market Surge
GlobeNewswire
·
May 31, 2025
Image by PAIRMiner STUTTGART, Germany, May 31, 2025 (GLOBE NEWSWIRE) -- As Bitcoin prices rise past key resistance levels, investor interest in digital assets is once again on the upswing. PAIRMiner, a cloud-based cryptocurrency mining platform, is helping …
Silicon Valley Hair Institute Announces Updated Content on Eyebrow Transplantation
EIN Presswire
·
May 31, 2025
Silicon Valley Hair Institute is excited to announce updated content for eyebrow transplantation. SAN FRANCISCO, CA, UNITED STATES, May 30, 2025 /EINPresswire.com/ -- Silicon Valley Hair Institute, the Bay Area leader in hair transplant and replacement …
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
GlobeNewswire
·
May 31, 2025
Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p<0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of locoregional and distant recurrence, respectively, compared to …
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
GlobeNewswire
·
May 31, 2025
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation Vepdegestrant was …
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma
GlobeNewswire
·
May 31, 2025
Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median …
Une analyse « Late Breaking » démontre les caractéristiques associées à la survie globale à long terme des patients avec un adénocarcinome pancréatique métastatique traités par Onivyde®
GlobeNewswire
·
May 31, 2025
L’essai de Phase III NAPOLI 3 est la plus grande étude interventionnelle réalisée à ce jour avec la plus longue période de suivi des patients avec un adénocarcinome pancréatique métastatique1. L’analyse post-hoc de l’étude NAPOLI 3 a permis de déterminer …
Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma
GlobeNewswire
·
May 31, 2025
Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to >2.5 years …
ImPact Biotech Presents Interim Analysis from Phase 3 ENLIGHTED Study of Padeliporfin VTP in LG UTUC at ASCO 2025
GlobeNewswire
·
May 31, 2025
– Complete response (CR) observed in 73% (27/37) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed the Induction Treatment Phase (ITP) – – Padeliporfin VTP treatment continues to be safe and well-tolerated, …
Harbinger Health Showcases Multi-Cancer Early Detection Performance in High-Risk Populations at ASCO 2025
GlobeNewswire
·
May 31, 2025
Reflex blood-based multi-cancer early detection (MCED) test demonstrated clinically meaningful per-cancer Positive Predictive Value (PPV) and early-stage sensitivity for multiple cancers with elevated incidence and mortality in a high-risk population Data …
Xilio Therapeutics Announces Updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
GlobeNewswire
·
May 31, 2025
26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases Deep and durable responses ongoing for up to 37 weeks through the data cutoff, …
Readers' Favorite Announces a Five-Star Rating for Award-Winning ‘Disrupt with Impact’ by Roger Spitz
EIN Presswire
·
May 30, 2025
Roger Spitz’s Bestselling ‘Disrupt with Impact: Achieve Business Success in an Unpredictable World’ Awarded Five-Star Rating from Readers’ Favorite SAN FRANCISCO, CA, UNITED STATES, May 30, 2025 /EINPresswire.com/ -- Following a string of accolades - …
Log-hub and OPTANO: A Unified Approach to Smarter, End-to-End Supply Chain Optimization
EIN Presswire
·
May 30, 2025
Log-hub and OPTANO have partnered to support supply chain professionals with a flexible, end-to-end approach to network design and optimization. SCHINDELLEGI, SWITZERLAND, May 31, 2025 /EINPresswire.com/ -- Log-hub and OPTANO have joined forces to offer …
Présentation du bracelet chrétien Tap2Read : un bracelet innovant pour des inspirations quotidiennes
EIN Presswire
·
May 30, 2025
Présentation du bracelet chrétien Tap2Read : un bracelet innovant pour des inspirations quotidiennes IKEJA, LAGOS, NIGERIA, May 30, 2025 /EINPresswire.com/ -- Dans un monde rempli d’incertitude, de stress, d’anxiété, de dépression et de distractions, …